Brain Classic NM Flashcards
AD FDG
Bilateral posterior parieto - temporal cortex
Posterior cingulate gyrus
Frontal lobe (advanced)
FDG 100% vs SPECT 90% sensitivity in discriminating AD patients
DLB FDG
Medial occipital cortex
FTD FDG
Fronto - temporal regions
Amyloid plaques in cortical gray matter
AD 100%
DLB 50-70%
Normal elderly
Amyloid imaging tracers
DD AD vs FTD
Identify MCI who will convert to AD
Early diagnosis of AD
C11PiB - - more sensitive than FDG
NeuraCeq
Amyvid
Vizamyl
NeuraCeq
F-florbetaben
8 mCi 120 min
Amyvid
F-florbetapir
10 mCi 45 min
Binding similar to PiB
Vizamyl
F-flutemetamol
5 mCi 90 min
Clinically diagnosed AD vs MCI in healthy elderly
Amyloid imaging AD
Frontal, parietal, temporal cortex
No dd AD vs DLB - - DatScan - - bilateral striatum - - AD
Amyloid imaging DLB
AD-like atrophy in parahippocampal area,
Lateral temporal, parietal cortex
Reduced Dat uptake
Amyloid imaging FTD
No amyloid - - no uptake
Brain SPECT tracers AD
Tc-ECD
TC-HMPAO
Both are small, lipophilic, neutral molecules - - cross intact BBB
Fast washout from extra-cerebral tissue, high contrast grey/white
Reduced perfusion in temporoparietal and frontal areas
DatScan preparation and protocol
I123-FP-CIT - cocaine analog
Thyroid block - lugol 100 mg or potassium perchlorate 400 mg 30-60 min before tracer injection
FOV with radius <16 cm, total time 30-45 min, min 1.5 ml counts
Scan after 3-6h when striatal/occipital binding ratio is stable
Sertraline in DatScan
Increase uptake but not interfere with visual presentation
Reduce binding to presinaptic dopamine transporter Dat
Cocaine, amphetamine, methylphenidate, ephedrine, phentermine
Anti Parkinson drug do not interfere with binding!!
FDOPA PD
Presynaptic dopamine transporter imaging
5 mCi 60-90 min
Striatal activity due to activity of AADC (aromatic amino acid decarboxylase)
Transport into storage vesicle by VMAT2
Reduced striatal uptake - - PD
Biomarker for in vivo striatal dopamine level
Postsynaptic D2 dopaminergic imaging tracer PD
Dd PD (presynaptic) and Parkinson plus (postsynaptic)
C11-raclopride
I123 - iodobenzamide = IBZM
Increased binding to putamen contralateral to more affected body side
Degeneration of presynaptic (PD untreated) - - upregulation of postsynaptic
I123 MIBG PD
Myocardial uptake - - no PD
Degeneration of adrenergic post-ganglion pathways - - no cardiac uptake - - PD
Presence of LB - hallmark of PD
Marker of DLB
PD symptoms
Bradykinesia
Rest tremor
Rigidity
Gait abnormality
Vascular cause of PD
Poor response to L-dopa
DatScan normal
Comma shaped uptake with symmetric borders
Rule out PD and DLB - - AD